Arcutis Biotherapeutics, Inc.

Approval Confirmed

ZORYVE (roflumilast) Cream 0.3%

Plaque Psoriasis in children (age 2+)

Resolved

8days ago

Approval decision · Jun 29, 2026

What's at stake A final FDA approval decision on ZORYVE (roflumilast) Cream 0.3% for Plaque Psoriasis in children (age 2+) is expected Jun 29, 2026.

Primary source · Press release verified 16h ago

“FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2”